{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Spero Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"SPRO"},"Address":{"label":"Address","value":"675 MASSACHUSETTS AVENUE,14TH FLOOR, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 857 242-1600"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital."},"CompanyUrl":{"label":"Company Url","value":"https://www.sperotherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Angela Talley","title":"Senior Vice President-Clinical Development"},{"name":"Kamal Hamed","title":"Chief Medical Officer"},{"name":"Satyavrat Shukla","title":"President, Chief Executive Officer & Director"},{"name":"Timothy Keutzer","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}